文献速递白血病

优化KMT2A重排儿童急性髓系白血病的细胞遗传学风险分层

Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性国际研究(2005-2016年)纳入1256例KMT2A重排儿童急性髓系白血病患者,旨在验证已知重现性KMT2A融合及额外细胞遗传学异常(ACA)的预后价值,并定义新的重现性融合和ACA。研究定义了3个新的KMT2A重排组,13组间5年无事件生存率差异显著(21.8%-76.2%,P<.01);ACA发生于46.8%的1200例核型完整患者,与较差总生存相关(56.8% vs 67.9%,P<.01)。多变量分析确认4q21/KMT2A::AFF1、6q27/KMT2A::AFDN、10p12/KMT2A::MLLT10、10p11.2/KMT2A::ABI1和19p13.3/KMT2A::MLLT1与不良结局独立相关。

要点

  • 13个KMT2A重排组5年无事件生存率21.8%-76.2%,差异显著(P<.01)。
  • ACA见于46.8%的1200例核型完整患者,与较差总生存相关(56.8% vs 67.9%,P<.01)。
  • 新发现独立不良预后ACA:单体10、三体1/6/16/X、add(12p)、del(9q)。

核心结论

  • 研究提供证据将5种不良风险KMT2A融合纳入KMT2A重排儿童AML的细胞遗传学风险分层。
  • 建议将1q21/KMT2A::MLLT11从有利风险修订为中等风险。
  • 建议细化9p22/KMT2A::MLLT3 AML的风险分层。
  • 未来研究应验证新发现ACA与结局的关联并揭示KMT2A融合及ACA的生物学发病机制。

研究设计与样本

  • 回顾性国际柏林-法兰克福-明斯特研究组研究,纳入2005-2016年1256例KMT2A重排儿童急性髓系白血病患者。
  • 旨在验证已知重现性KMT2A融合及额外细胞遗传学异常的预后价值,并定义新的重现性融合和ACA。

主要发现

  • 与既往研究相比,新定义3个重现性KMT2A重排组:Xq24/KMT2A::SEPT6、1p32/KMT2A::EPS15和17q12/t(11;17)(q23;q12)。
  • 13个KMT2A重排组5年无事件生存率21.8%-76.2%,差异显著(P<.01)。
  • ACA发生于46.8%的1200例核型完整患者,与较差总生存相关(56.8% vs 67.9%,P<.01)。
  • 多变量分析确认4q21/KMT2A::AFF1、6q27/KMT2A::AFDN、10p12/KMT2A::MLLT10、10p11.2/KMT2A::ABI1和19p13.3/KMT2A::MLLT1与不良结局独立相关;1q21/KMT2A::MLLT11的有利预后和三体19的不良预后未获确认。
  • 新发现独立不良预后ACA包括单体10、三体1、6、16和X、add(12p)和del(9q)。

关键数值与推荐

  • 13个KMT2A重排组5年无事件生存率范围为21.8%-76.2%(P<.01)。
  • ACA存在于46.8%的1200例核型完整患者中,ACA组总生存56.8% vs 无ACA组67.9%(P<.01)。
  • 多变量分析确认5种KMT2A融合(4q21/KMT2A::AFF1、6q27/KMT2A::AFDN、10p12/KMT2A::MLLT10、10p11.2/KMT2A::ABI1、19p13.3/KMT2A::MLLT1)与不良结局独立相关。
  • 新发现独立不良预后ACA:单体10、三体1、6、16、X、add(12p)、del(9q)。
  • 在9p22/KMT2A::MLLT3患者中,FAB-M5与有利结局独立相关,三体6和诱导结束时MRD与不良结局独立相关。

临床怎么用

  • 研究提供证据将5种不良风险KMT2A融合纳入KMT2A重排儿童AML的细胞遗传学风险分层。
  • 建议将1q21/KMT2A::MLLT11从有利风险修订为中等风险。
  • 建议细化9p22/KMT2A::MLLT3 AML的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A comprehensive international consensus on the cytogenetic risk-group stratification of KMT2A-rearranged (KMT2A-r) pediatric acute myeloid leukemia (AML) is lacking. This retrospective (2005-2016) International Berlin-Frankfurt-Münster Study Group study on 1256 children with KMT2A-r AML aims to validate the prognostic value of established recurring KMT2A fusions and additional cytogenetic aberrations (ACAs) and to define additional, recurring KMT2A fusions and ACAs, evaluating their prognostic relevance. Compared with our previous study, 3 additional, recurring KMT2A-r groups were defined: Xq24/KMT2A::SEPT6, 1p32/KMT2A::EPS15, and 17q12/t(11;17)(q23;q12). Across 13 KMT2A-r groups, 5-year event-free survival probabilities varied significantly (21.8%-76.2%; P < .01). ACAs occurred in 46.8% of 1200 patients with complete karyotypes, correlating with inferior overall survival (56.8% vs 67.9%; P < .01). Multivariable analyses confirmed independent associations of 4q21/KMT2A::AFF1, 6q27/KMT2A::AFDN, 10p12/KMT2A::MLLT10, 10p11.2/KMT2A::ABI1, and 19p13.3/KMT2A::MLLT1 with adverse outcomes, but not those of 1q21/KMT2A::MLLT11 and trisomy 19 with favorable and adverse outcomes, respectively. Newly identified ACAs with independent adverse prognoses were monosomy 10, trisomies 1, 6, 16, and X, add(12p), and del(9q). Among patients with 9p22/KMT2A::MLLT3, the independent association of French-American-British-type M5 with favorable outcomes was confirmed, and those of trisomy 6 and measurable residual disease at end of induction with adverse outcomes were identified. We provide evidence to incorporate 5 adverse-risk KMT2A fusions into the cytogenetic risk-group stratification of KMT2A-r pediatric AML, to revise the favorable-risk classification of 1q21/KMT2A::MLLT11 to intermediate risk, and to refine the risk-stratification of 9p22/KMT2A::MLLT3 AML. Future studies should validate the associations between the newly identified ACAs and outcomes and unravel the underlying biological pathogenesis of KMT2A fusions and ACAs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Weelderen RE, Harrison CJ, Klein K, et al. Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia. Blood Adv. 2024. PMID: 38621200. doi:10.1182/bloodadvances.2023011771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。